A landmark randomized Phase III clinical trial has demonstrated that a maintenance chemotherapy rhabdomyosarcoma strategy significantly improves survival rates in children at high risk for cancer recurrence. Adding six months of low dose maintenance chemotherapy after initial treatment increased the five year overall survival rate from 73.7% to 86.5%. The findings were selected for presentation at the American Society of Clinical Oncology Annual Meeting Plenary Session, reserved for studies with the greatest potential to impact patient care. According to the Mayo Clinic<\/a>, rhabdomyosarcoma is the most common soft tissue sarcoma in children, making treatment advances in this area especially significant.<\/p>\n Rhabdomyosarcoma originates in muscle tissue and can develop in any part of the body, though it most commonly appears in the head, neck, pelvis, and abdomen. It accounts for approximately 4% of all childhood cancers, with around 350 children diagnosed each year in the United States.<\/p>\n The overall prognosis is generally favorable. About 80% of children can be cured with modern treatment combining high dose chemotherapy, radiation, and surgery. However, for children who present with metastasis at diagnosis or experience recurrence after initial treatment, the cure rate drops sharply to only 20 to 30%. This high risk subgroup is precisely where the maintenance chemotherapy rhabdomyosarcoma strategy was tested.<\/p>\n The most striking finding from the trial is the improvement in five year overall survival. In the standard treatment group, 73.7% of patients were alive at five years. In the maintenance chemotherapy rhabdomyosarcoma group, that figure rose to 86.5%. Children who survive five years without recurrence are considered cured, as tumor relapse is very rare beyond that point.<\/p>\n Five year disease free survival, defined as survival without tumor recurrence or death from any cause, was 68.8% in the standard group versus 77.6% in the maintenance therapy group. This improvement in disease free survival complements the overall survival gains and confirms the maintenance chemotherapy rhabdomyosarcoma approach produces durable benefit.<\/p>\n The study enrolled patients at high risk for recurrence due to large tumors located in anatomically difficult treatment sites such as the head. After completing standard initial treatment, 371 patients, 79% of whom were 10 years old or younger, were randomly assigned to either stop treatment or receive six months of maintenance therapy with intravenous vinorelbine and oral cyclophosphamide at low doses.<\/p>\n The most common side effect in the maintenance chemotherapy rhabdomyosarcoma group was low blood cell count, which was generally mild. Febrile neutropenia occurred in 25% of patients. Notably, infection rates during maintenance treatment were lower than those observed after initial standard chemotherapy, and neurologic side effects resolved after treatment ended. Long term monitoring for late effects continues.<\/p>\n As lead author Gianni Bisogno, MD, PhD, professor at the University Hospital of Padova and Chair of the European Paediatric Soft Tissue Sarcoma Study Group noted, rhabdomyosarcoma has been treated the same way for more than 30 years. Although various approaches have been attempted, this is the first randomized trial to demonstrate improved outcomes by using existing medicines in new ways, establishing a new standard of care for the maintenance chemotherapy rhabdomyosarcoma population in Europe.<\/p>\n The findings have already changed the standard of care across 14 countries in Europe. In the United States, where treatment protocols differ somewhat, further study is needed to determine how best to integrate maintenance therapy into existing approaches. This creates an important opportunity for clinical research to close the gap between European and US practice.<\/p>\nWhat Is Rhabdomyosarcoma<\/h3>\n
5 Proven Maintenance Chemotherapy Rhabdomyosarcoma Trial Results<\/h3>\n
1. Overall Survival Improved From 73.7% to 86.5%<\/h4>\n
2. Disease-Free Survival Also Improved Significantly<\/h4>\n
3. The Trial Enrolled 371 High Risk Patients Aged 6 Months to 21 Years<\/h4>\n
4. Side Effects Were Manageable<\/h4>\n
5. This Is the First Randomized Trial to Show Improved Outcomes in 30 Years<\/h4>\n
What Comes Next<\/h3>\n